Topic: chronic disease

Older dog and cat

BI aims to boost chronic disease portfolio post-Sanofi asset swap

On New Year’s Day, Sanofi and Boehringer Ingelheim closed a $12.5 billion asset swap that had been in the works for a year, giving the closely held Germany-based BI a suite of drugs to treat farm and companion animals. Here's what's next for the company, which had suffered some setbacks on the human side of the business prior to the deal.